About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
GRACE
cancergrace.org
Podcast Series
Targeted Therapies in Lung Cancer 2023
ASCO® 2023
Lung Cancer OncTalk
Blood Cancer OncTalk
2022 Melanoma Video Library
OncTalk 2022
ASCO Lung Review 2022
ASCO and ESMO Lung Recap
2021 Targeted Therapies Patient Forum
COVID-19
Lung
Hematologic Oncology
Head and Neck
Brain
Palliative
Genitourinary
General
Breast
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Choosing CAR T-Cell or Bispecifics After Standard Myeloma Therapy Exhaustion: Panel Discussion
By
GRACE
FEATURING
Aaron Goodman
,
Sridevi Rajeeve
,
Marco Ruiz
By
GRACE
FEATURING
Aaron Goodman
,
Sridevi Rajeeve
,
Marco Ruiz
11 views
March 11, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
20:00
Exelixis
Child-Pugh Classification and its Role in Treatment Decisions in Pat…
Feat.
P. Gholam
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Blood Cancer OncTalk
07:52
GRACE
Experts Discuss Their Approach to Auto-Transplant for Young Standar…
Feat.
A. Goodman,
S. Rajeeve,
M. Ruiz
08:35
GRACE
Oncologists' Guidance on Treating Smoldering Myeloma: Panel Dis…
Feat.
A. Goodman,
A. Taneja,
T. Phillips
05:08
GRACE
Choosing CAR T-Cell or Bispecifics After Standard Myeloma Therapy Ex…
Feat.
A. Goodman,
S. Rajeeve,
M. Ruiz
05:19
GRACE
A Summary of Efficacy and Safety Data From Bispecific Antibodies in …
Feat.
S. Rajeeve
03:25
GRACE
The Future of Bispecific Antibodies in Myeloma
Feat.
S. Rajeeve
05:38
GRACE
Epcoritamab in NHL - Incidence and Management of CRS
Feat.
T. Phillips
04:16
GRACE
Mosunetuzumab for R/R Follicular Lymphoma
Feat.
T. Phillips
04:04
GRACE
Efficacy of Epcoritamab and Glofitamab in R/R DLBCL
Feat.
T. Phillips
03:28
GRACE
Updates on Bispecific Antibodies in Myeloma
Feat.
S. Rajeeve
05:38
GRACE
Overview on Current Immunotherapy Options in Myeloma
Feat.
S. Rajeeve
03:06
GRACE
The Impact of Transplant on Survival in Myeloma and Lymphoma
Feat.
M. Ruiz
06:55
GRACE
Current Utility of Autologous Bone Marrow Transplants in Myeloma and…
Feat.
M. Ruiz
07:28
GRACE
Overview and Logistics of Bone Marrow Transplant
Feat.
M. Ruiz
04:13
GRACE
The TRIANGLE Study: Ibrutinib Maintenance for MCL
Feat.
T. Phillips
05:28
GRACE
3L Treatment for Mantle Cell Lymphoma
Feat.
T. Phillips
07:11
GRACE
CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…
Feat.
A. Goodman,
A. Jeong,
S. Rajeeve
12:02
GRACE
Tailoring Chemotherapy for Geriatric Patients With Advanced Stage Ag…
Feat.
M. Tsang
07:55
GRACE
The Prevalence of Mantle Cell Lymphoma
Feat.
T. Phillips
23:42
GRACE
Multiple Myeloma & Cellular Therapies: A Patient-Centric Primer
Feat.
S. Rajeeve
16:29
CancerGRACE
Small Molecule Targeted Therapies in AML
Feat.
A. Jeong
22:02
GRACE
Considerations for Older Adults With Aggressive Lymphoma
Feat.
M. Tsang
26:08
GRACE
2023 Updates on Advances in Multiple Myeloma
Feat.
S. Kumar
